GuideAI Health Corp. Completes Business Combination and Subscription Receipt Offering

GuideAI Health Corp. announced the successful completion of a significant business combination transaction with GuideAI Health, Inc., along with a concurrent subscription receipt offering. The Corporation, formerly known as 1532139 B.C. Ltd, has changed its corporate name to “GuideAI Health Corp.” following this merger. This development marks a strategic milestone in the company's mission to develop and deploy artificial intelligence solutions that improve the detection and management of vascular and cardiovascular disease.

The transaction was completed by way of a plan of arrangement under the Business Corporations Act (British Columbia), under which a wholly-owned subsidiary of the Corporation acquired all of the issued and outstanding securities of Guide Health. The Corporation also filed and obtained a receipt for its final non-offering prospectus dated June 12, 2026, with the securities regulatory authorities in British Columbia, Alberta, and Ontario, qualifying the distribution of Subscription Receipts. These steps strengthen the company's corporate structure and solidify the legal framework for future growth and operations.

Immediately following the closing of the transaction and the offering, GuideAI Health Corp. has an aggregate of 53,551,525 common shares issued and outstanding. The Corporation has obtained conditional approval from Cboe Canada (the “Exchange”) for the listing of its Common Shares. However, the listing remains subject to the Corporation fulfilling all of the customary requirements of the Exchange. The brokered private placement (the “Offering”) generated gross proceeds of $5,150,000 from the issuance of 5,150,000 subscription receipts at an issue price of $1.00 per subscription receipt. Each Subscription Receipt will be converted into one Common Share upon the satisfaction or waiver of certain escrow release conditions.

This strategic move underscores the increasing importance of artificial intelligence technologies in the healthcare sector. GuideAI Health, Inc., founded in 2024 and headquartered in Boston, Massachusetts, is known for developing an AI-powered platform designed to improve the early detection and diagnosis of chronic vascular disease. Luke Higgins, CEO of the company, stated, “Our vision is to make advanced vascular and cardiovascular intelligence available to every healthcare provider, not just major academic centers.” This combination is expected to significantly enhance GuideAI Health Corp.'s capacity to realize this vision.

The use of artificial intelligence in health technologies is garnering significant global interest due to its potential to improve patient outcomes and reduce healthcare costs. GuideAI Health Corp.'s work in this area is critically important for advancing early diagnosis and personalized treatment methods. Market analysts highlight AI's potential to revolutionize healthcare, with expectations that such combinations will accelerate innovation in the sector and create new opportunities for investors. In the coming period, the company's listing process on Cboe Canada and the progress of its AI solutions in clinical applications will be closely monitored.